Antibodies illuminate a 30-year inflammatory bowel disease mystery

Why does this matter for people with IBD?

IBD is an umbrella term for Crohn's disease and ulcerative colitis, chronic conditions affecting about 500,000 people in the UK and millions worldwide. Symptoms often begin in adolescence or early adulthood, and patients may face lifelong medical challenges, repeated hospital visits, immune-suppressing medicines and sometimes surgery.

Many try several therapies without lasting relief, imposing a substantial burden on patients and significant costs for healthcare systems. The findings indicate that IBD appears to include several biologically distinct conditions arising through different processes, which could support more tailored diagnoses and treatments.

What did rare inherited disorders reveal?

More than a decade of work on rare inherited disorders of inflammation guided the investigation. Genetic defects in IL-10 or the protein that receives its signal had been found in young children with severe IBD; later, researchers recognized that neutralizing autoantibodies produced similar effects in two girls with colitis.

Professor Sophie Hambleton, professor of pediatrics and immunology at Newcastle University, said:

This discovery shows how the study of rare, inherited disorders can shed new light on common conditions.

The groundwork was laid over 10 years ago when genetic defects in IL-10 or its receptor were found in young children with severe IBD. Later, we realized that neutralizing autoantibodies against IL-10 were mimicking this effect in 2 little girls with colitis.

These clues helped the team test whether antibodies could mimic inherited faults in a much larger group.

Could a blood test lead to more targeted treatment?

The researchers view the results as a foundation for a blood test that identifies people whose disease is associated with IL-10 antibodies. Earlier recognition could help doctors select treatments aimed at the underlying immune malfunction, although neither the test nor a new therapy has yet been established.

One strategy would target the antibodies or the immune cells that produce them, potentially reducing repeated therapies, admissions, surgery and the need for ongoing immune suppression.

Dr Rainer Doffinger, a clinical immunologist at Cambridge University Hospitals NHS Foundation Trust, assessed the possible clinical and economic effects of earlier, targeted treatment:

By identifying patients early and giving them targeted treatment, we could reduce reliance on expensive ongoing therapy and prevent complications.

Even modest reductions in biologic treatment, admissions and surgery could translate into savings of many millions of pounds annually for the NHS, alongside the major benefits for patients through fewer interventions, improved quality of life or even durable remission.

Here, biologic treatment means an immune-targeted medicine.

Professor Simon Travis, professor of clinical gastroenterology at Oxford and the Kennedy Institute of Rheumatology, said:

This is the most exciting discovery in a lifetime specialising in IBD. It means that we can now identify a group where we know what is causing the disease and that creates a real opportunity to change how we manage this disease.

Personalized care could eventually rely on biological tests rather than symptoms alone to identify what drives each patient's inflammation. The mechanism applies to the subgroup with elevated neutralizing antibodies, not to every form of IBD.

The study, “Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease,” appeared in The New England Journal of Medicine, volume 394, issue 22, page 2212, in 2026. Its DOI is 10.1056/NEJMoa2513654. The University of Oxford released the results on October 26, 2026.

Work involved Oxford's Nuffield Department of Medicine, Newcastle University's Translational and Clinical Research Institute and Cambridge University Hospitals' Department of Immunology. The National Institute for Health and Care Research Biomedical Research Centres in Oxford, Cambridge and Newcastle provided funding.

The immediate advance is a biological explanation; the next test is whether it becomes a more precise way to treat thousands of patients.